Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cyclophosphamide + lenalidomide
- Development stage
- Unknown
- Lead developer
- GIMEMA
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The FCL regimen is a combination therapy consisting of the purine analog fludarabine, the alkylating agent cyclophosphamide, and the immunomodulatory drug (IMiD) lenalidomide. This specific combination was developed and evaluated in Phase I/II clinical trials (such as the LLC0606 study) by the Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The regimen builds upon the standard fludarabine and cyclophosphamide (FC) backbone by adding lenalidomide, which acts as a molecular glue to enhance immune-mediated anti-tumor activity and exert direct anti-proliferative effects on malignant B-cells. Lenalidomide's primary mechanism involves binding to the Cereblon E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos.
- Brand names
- Revlimid
- Other names
- FCL regimenlenalidomide + fludarabine + cyclophosphamide
02
Targets
DNACRBN (Cereblon)
Beyond the preview
Go deeper on fludarabine + cyclophosphamide + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cyclophosphamide + lenalidomide.